• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Postdoctoral Position Available: Pulmonary Drug Delivery

    Postdoctoral Position Available: Pulmonary Drug Delivery

    16-Apr-2019

    Post-doctoral Fellow Position Open in Pulmonary Drug Delivery, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium

    The Advanced Drug Delivery & Biomaterials research group of the Louvain Drug Research Institute of the Université catholique de Louvain (UCLouvain) in Brussels, Belgium, aims to develop new drug delivery systems for two main challenges of the pharmaceutical industry, namely the delivery of i) biotech-based drugs (proteins, vaccines, nucleic acids) and ii) poorly soluble drugs. The scientific approach is multidisciplinary and mechanistic-driven. It involves i) the development of new formulations, ii) their physico-chemical characterization iii) the demonstration of their efficacy in vitro and in vivo iii) the understanding of their mechanisms of action and interactions with biological systems. The research themes include transdermal drug delivery, polymeric nanocarriers, pulmonary drug delivery and drug delivery in tissue engineering. 

    The research of Prof. R. Vanbever within the Advanced Drug Delivery & Biomaterials research group focuses on pulmonary drug administration aspects, that is, the formulation of inhalation dry powders, the study of the pulmonary fate of diverse molecules following delivery to the lung in vivo in rodents, the assessment of the potential of vaccine delivery to the lung for protection against respiratory infections as well as the development of formulation strategies to sustain drug release within the lung. This latter topic has especially been developed within Rita Vanbever’s group these last years, in particular with the study of the impact of the PEGylation of proteins and small molecule drugs on their residence time in the lung and on their therapeutic efficacy locally.

    Job Description:

    Idiopathic pulmonary fibrosis (IPF) is a rare, not curable, chronic lung disease. The INAT project aims to develop a novel nanomedicine, to be delivered locally and non-invasively via aerosols into the lungs to improve its therapeutic index (high efficacy, low side effects). This nanomedicine combines an innovative nanoparticle, which is biodegradable and highly effective, and an oligonucleotide to target a profibrosis mediator. The nanomedicine will be formulated for inhalation in humans and its toxicity and efficacy tested pre-clinically. The INAT consortium synergistically combines the efforts of 3 academic labs with complementary expertise in aerosolized medicine and 2 industry partners, whose platform technologies will be merged. This will allow to develop a novel nanomedicine for inhalation in humans and to achieve its robust preclinical evaluation for the treatment ofIPF.

    This 3-year project is funded by the European Commission Horizon 2020 under the EuroNanoMed III call (http://euronanomed.net/funded-projects/). It is coordinated by Dr. Nathalie Heuzé-Vourc’h of the University of Tours (France) and performed in collaboration with Dr. Otmar Schmid of the German Research Center for Environmental Health, Gilles Divita of DIV’INCELL (France) and Jonas Renz of Secarna Pharmaceuticals (Germany). You will receive a 12 month postdoctoral fellowship with a net allocation ranging from 2 490€ to 2 600€ per month, according to your seniority. The contract will start July 2nd 2019 and will be renewable once for a total of 24months.

    Your Profile:

    • You have recently obtained a Ph.D. degree in pharmaceutical, biomedical or biological sciences.
    • You have laboratory experience in in vivo drug delivery and toxicity studies in mice, confocal laser scanning microscopy, flow cytometry.
    • You possess good communication skills in English.

    If you are interested, please send a letter of application along with your curriculum vitae and the names and contact information of 2 references, by email to:

    Prof. Rita Vanbever, rita.vanbever@uclouvain.be

    Advanced Drug Delivery & Biomaterials - Louvain Drug Research Institute - Université catholique de Louvain - Brussels - Belgium

    Visit our website to learn more about our research.